

# David H Abramson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2451216/publications.pdf>

Version: 2024-02-01

208  
papers

9,820  
citations

47006

47  
h-index

43889

91  
g-index

211  
all docs

211  
docs citations

211  
times ranked

4871  
citing authors

#	ARTICLE	IF	CITATIONS
1	Uveal lymphoid hyperplasia: treatment with combination antibiotics and steroids. <i>British Journal of Ophthalmology</i> , 2023, 107, 786-789.	3.9	1
2	Intra-arterial chemotherapy for retinoblastoma. <i>Journal of NeuroInterventional Surgery</i> , 2023, 15, 303-304.	3.3	5
3	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates. <i>Cornea</i> , 2022, 41, 792-801.	1.7	6
4	Treatment of Retinoblastoma: What Is the Latest and What Is the Future. <i>Frontiers in Oncology</i> , 2022, 12, 822330.	2.8	30
5	Cell Free DNA (cfDNA) in the Blood of Retinoblastoma Patients The Robert M. Ellsworth Lecture. <i>Ophthalmic Genetics</i> , 2022, 43, 731-735.	1.2	7
6	Combination intravitreal melphalan and bevacizumab for cutaneous metastatic melanoma to the vitreous and retina. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 26, 101519.	0.7	1
7	Cancer-Causative Mutations Occurring in Early Embryogenesis. <i>Cancer Discovery</i> , 2022, 12, 949-957.	9.4	21
8	Second Primary Neoplasms in Retinoblastoma: Effect of Gene and Environment. , 2022, , 7941-7952.		0
9	Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). <i>Journal of Clinical Oncology</i> , 2022, 40, 3839-3847.	1.6	11
10	Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 27, 101657.	0.7	3
11	Is intravitreal topotecan toxic to retinal function?. <i>British Journal of Ophthalmology</i> , 2021, 105, 1016-1018.	3.9	8
12	A decision process for drug discovery in retinoblastoma. <i>Investigational New Drugs</i> , 2021, 39, 426-441.	2.6	11
13	Low-grade glioma: A rare second tumor in retinoblastoma survivors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28770.	1.5	0
14	General cancer screening practices among adult survivors of retinoblastoma: Results from the Retinoblastoma Survivor Study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28873.	1.5	2
15	Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. <i>British Journal of Cancer</i> , 2021, 124, 1312-1319.	6.4	16
16	Second Primary Neoplasms in Retinoblastoma: Effect of Gene and Environment. , 2021, , 1-12.		0
17	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
18	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. <i>Cancers</i> , 2021, 13, 673.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in Retinoblastoma. <i>Ophthalmology Science</i> , 2021, 1, 100015.	2.5	16
20	Benign Tumors in Long-Term Survivors of Retinoblastoma. <i>Cancers</i> , 2021, 13, 1773.	3.7	5
21	Prelaminar and Postlaminar Invasion of Retinoblastoma. <i>Ophthalmology Retina</i> , 2021, 5, 387.	2.4	0
22	Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. <i>Neurology</i> , 2021, 96, 1091-1093.	1.1	3
23	Increased Risk of Skin Cancer in 1,851 Long-Term Retinoblastoma Survivors. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2849-2857.e3.	0.7	6
24	Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2021, 5, 1187-1195.	2.4	5
25	An In Utero Presentation of Trilateral Retinoblastoma. <i>Ophthalmology Retina</i> , 2021, 5, 831-832.	2.4	1
26	Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. <i>JAMA Ophthalmology</i> , 2021, 139, 1126.	2.5	10
27	Association of Plasma Circulating Tumor DNA With Diagnosis of Metastatic Uveal Melanoma. <i>JAMA Ophthalmology</i> , 2021, 139, 1244-1245.	2.5	4
28	Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression. <i>Nature Communications</i> , 2021, 12, 5402.	12.8	34
29	Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis). <i>American Journal of Ophthalmology Case Reports</i> , 2021, 23, 101125.	0.7	2
30	Successful Treatment of Massive Choroidal Invasion in Retinoblastoma with Intra-arterial Chemotherapy (Ophthalmic Artery Chemosurgery). <i>Ophthalmology Retina</i> , 2021, 5, 936-939.	2.4	5
31	RB1 Circulating Tumor DNA in the Blood of Patients with Unilateral Retinoblastoma. <i>Ophthalmology Science</i> , 2021, 1, 100042.	2.5	6
32	Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing. <i>Cancers</i> , 2021, 13, 149.	3.7	27
33	Retinoblastoma management in 13q deletion syndrome patients using superselective chemotherapies and other cancer-directed interventions. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28845.	1.5	2
34	TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA. <i>Retina</i> , 2021, 41, 208-212.	1.7	6
35	Isolated Abducens Nerve Palsy Following Pembrolizumab. <i>Neuro-Ophthalmology</i> , 2020, 44, 182-185.	1.0	15
36	Intravitreal Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition. <i>Ophthalmology</i> , 2020, 127, 240-248.	5.2	22

#	ARTICLE	IF	CITATIONS
37	Impact of enucleation on adult retinoblastoma survivors's quality of life: A qualitative study of survivors' perspectives. <i>Palliative and Supportive Care</i> , 2020, 18, 322-331.	1.0	7
38	MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. <i>Ocular Oncology and Pathology</i> , 2020, 6, 159-163.	1.0	8
39	Magnetic Resonance Imaging Screening for Trilateral Retinoblastoma. <i>Ophthalmology Retina</i> , 2020, 4, 327-335.	2.4	7
40	Hemodynamic Changes Associated with Mydriatic Eye Drop Administration in Anesthetized Pediatric Patients. <i>Ocular Oncology and Pathology</i> , 2020, 6, 203-209.	1.0	0
41	SUBFOVEAL CHOROIDAL THICKNESS AND VASCULAR ARCHITECTURE IN FELLOW EYES OF PATIENTS WITH CIRCUMSCRIBED CHOROIDAL HEMANGIOMA. <i>Retina</i> , 2020, 40, 758-764.	1.7	12
42	Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis. <i>Ocular Oncology and Pathology</i> , 2020, 6, 184-195.	1.0	4
43	Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. <i>Cancers</i> , 2020, 12, 2714.	3.7	27
44	Reply. <i>Ophthalmology</i> , 2020, 127, e106-e107.	5.2	2
45	Lacrimal sac adenocarcinoma managed with androgen deprivation. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100607.	0.7	2
46	Unilateral Retinoblastoma Metastatic to the Skull and Both Orbits. <i>Ophthalmology Retina</i> , 2020, 4, 1021.	2.4	1
47	Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28389.	1.5	16
48	Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects. <i>Advances in Biological Regulation</i> , 2020, 78, 100723.	2.3	5
49	Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100799.	0.7	9
50	Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma. <i>PLoS ONE</i> , 2020, 15, e0235016.	2.5	5
51	Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. <i>Cancer Medicine</i> , 2020, 9, 6093-6101.	2.8	32
52	Immune Checkpoint Inhibitor-Associated Optic Neuritis. <i>Ophthalmology</i> , 2020, 127, 1585-1589.	5.2	30
53	Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1549-1557.	5.2	24
54	Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. <i>British Journal of Ophthalmology</i> , 2019, 103, 488-493.	3.9	46

#	ARTICLE	IF	CITATIONS
55	Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2019, 37, 3436-3445.	1.6	19
56	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1989-1994.	1.1	10
57	GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas. <i>Ophthalmology</i> , 2019, 126, 759-763.	5.2	26
58	Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914-2016. <i>Journal of the National Cancer Institute</i> , 2019, 111, 961-969.	6.3	26
59	Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan. <i>Ocular Oncology and Pathology</i> , 2019, 5, 186-189.	1.0	4
60	Tridimensional Retinoblastoma Cultures as Vitreous Seeds Models for Live-Cell Imaging of Chemotherapy Penetration. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1077.	4.1	22
61	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	30.7	122
62	What's New in Intra-Arterial Chemotherapy for Retinoblastoma?. <i>International Ophthalmology Clinics</i> , 2019, 59, 87-94.	0.7	16
63	Fabrication of a custom brachytherapy appliance. <i>Journal of Prosthetic Dentistry</i> , 2019, 121, 535-537.	2.8	4
64	Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes. <i>PLoS ONE</i> , 2019, 14, e0210647.	2.5	5
65	Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017. <i>British Journal of Ophthalmology</i> , 2019, 103, 1272-1277.	3.9	32
66	Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma. <i>British Journal of Ophthalmology</i> , 2019, 103, 1266-1271.	3.9	8
67	Choroidal Invasion in Retinoblastoma Treated with Intrarterial Chemotherapy. <i>Ophthalmology Retina</i> , 2018, 2, 9.	2.4	2
68	Vision-Targeted Health-Related Quality of Life in Adult Survivors of Retinoblastoma. <i>JAMA Ophthalmology</i> , 2018, 136, 637.	2.5	13
69	Reply. <i>Ophthalmology</i> , 2018, 125, e31.	5.2	0
70	Clinicopathologic Correlation of Choroidal Invasion in Retinoblastoma. <i>Ophthalmology</i> , 2018, 125, 568.	5.2	2
71	Intravitreal chemotherapy and laser for newly visible subretinal seeds in retinoblastoma. <i>Ophthalmic Genetics</i> , 2018, 39, 353-356.	1.2	11
72	Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: the first 10 years. <i>British Journal of Ophthalmology</i> , 2018, 102, 272-275.	3.9	18

#	ARTICLE	IF	CITATIONS
73	Iris Mass in a 2-Year-Old. <i>Ophthalmology Retina</i> , 2018, 2, 905.	2.4	0
74	Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitreal Chemotherapy. <i>Neoplasia</i> , 2018, 20, 757-763.	5.3	50
75	Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery. <i>PLoS ONE</i> , 2018, 13, e0195395.	2.5	10
76	Growth patterns of survivors of retinoblastoma treated with ophthalmic artery chemosurgery. <i>PLoS ONE</i> , 2018, 13, e0197052.	2.5	3
77	<i>BRAF</i> , <i>NRAS</i> , and <i>GNAQ</i> Mutations in Conjunctival Melanocytic Nevi. , 2018, 59, 117.		27
78	Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. <i>PLoS ONE</i> , 2018, 13, e0197081.	2.5	68
79	Choroidal infarction following ophthalmic artery chemotherapy. <i>International Journal of Retina and Vitreous</i> , 2018, 4, 16.	1.9	5
80	Re: Skalet etÂal.: Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists (Ophthalmology. 2018;125:453-458). <i>Ophthalmology</i> , 2018, 125, e63-e64.	5.2	3
81	Clinicopathological Correlation of Choroidal Invasion in Retinoblastoma. <i>JAMA Ophthalmology</i> , 2018, 136, e180940.	2.5	0
82	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. <i>Blood</i> , 2018, 132, 49-49.	1.4	10
83	Efficacy and Toxicity of Intravitreal Chemotherapy for Retinoblastoma: Four-Year Experience. <i>Ophthalmology</i> , 2017, 124, 488-495.	5.2	88
84	Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma. <i>Ophthalmic Genetics</i> , 2017, 38, 16-21.	1.2	37
85	Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function. <i>British Journal of Ophthalmology</i> , 2017, 101, 623-628.	3.9	6
86	OCULAR PHARMACOLOGY OF CHEMOTHERAPY FOR RETINOBLASTOMA. <i>Retina</i> , 2017, 37, 1-10.	1.7	31
87	Retinoblastoma Vitreous Seed Clouds (Class 3). <i>Ophthalmology</i> , 2017, 124, 1548-1555.	5.2	32
88	SKP2 Activation by Thyroid Hormone Receptor $\beta$ 2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells. <i>Cancer Research</i> , 2017, 77, 6838-6850.	0.9	8
89	Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreal Chemotherapy. <i>JAMA Ophthalmology</i> , 2017, 135, 1426.	2.5	47
90	Selective ophthalmic artery chemosurgery (SOAC) for retinoblastoma: fluoroscopic time and radiation dose parameters. A baseline study. <i>Journal of NeuroInterventional Surgery</i> , 2017, 9, 1107-1112.	3.3	12

#	ARTICLE	IF	CITATIONS
91	Growth of Uveal Melanoma following Intravitreal Bevacizumab. <i>Ocular Oncology and Pathology</i> , 2017, 3, 117-121.	1.0	18
92	Vitreous Disease in Retinoblastoma. <i>Advances in Ophthalmology and Optometry</i> , 2017, 2, 177-195.	0.3	4
93	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	5.2	95
94	Anterior Segment Retinoblastoma. <i>Ophthalmology Retina</i> , 2017, 1, 561.	2.4	0
95	Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic) Tj ETQq1 1 0.784314 rgBT /Overlock 1.9 45	1.9	45
96	Anesthetic complications during general anesthesia without intravenous access in pediatric ophthalmologic clinic: assessment of 5216 cases. <i>Minerva Anestesiologica</i> , 2017, 83, 712-719.	1.0	4
97	An international survey of classification and treatment choices for group D retinoblastoma. <i>International Journal of Ophthalmology</i> , 2017, 10, 961-967.	1.1	30
98	Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery. <i>PLoS ONE</i> , 2016, 11, e0151343.	2.5	14
99	Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem) Tj ETQq1 1 0.784314 rgBT /Overlock 2.5 41	2.5	41
100	INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA. <i>Retinal Cases and Brief Reports</i> , 2016, 10, 357-360.	0.6	16
101	Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study. <i>Cancer</i> , 2016, 122, 773-781.	4.1	31
102	Classification of Vitreous Seeds in Retinoblastoma. <i>Ophthalmology</i> , 2016, 123, 1601-1605.	5.2	28
103	Reply. <i>Ophthalmology</i> , 2016, 123, e10-e11.	5.2	0
104	Twenty-Year Collaboration Between North American and South American Retinoblastoma Programs. <i>Journal of Global Oncology</i> , 2016, 2, 347-352.	0.5	9
105	Aicardi Syndrome. <i>Ophthalmology</i> , 2016, 123, 1645.	5.2	1
106	Update on Ophthalmic Oncology 2014. <i>Asia-Pacific Journal of Ophthalmology</i> , 2016, 5, 368-382.	2.5	5
107	Incidence of Orbital Recurrence After Enucleation or Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma-Reply. <i>JAMA Ophthalmology</i> , 2016, 134, 114.	2.5	5
108	Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. <i>PLoS ONE</i> , 2016, 11, e0146582.	2.5	108

#	ARTICLE	IF	CITATIONS
109	Retinoblastoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15021.	30.5	376
110	Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. <i>PLoS ONE</i> , 2015, 10, e0145436.	2.5	66
111	Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma. , 2015, 56, 4382.		18
112	Intraoperative High-Dose Rate of Radioactive Phosphorus 32 Brachytherapy for Diffuse Recalcitrant Conjunctival Neoplasms. <i>JAMA Ophthalmology</i> , 2015, 133, 283.	2.5	12
113	Efficacy and Toxicity of Second-Course Ophthalmic Artery Chemosurgery for Retinoblastoma. <i>Ophthalmology</i> , 2015, 122, 1016-1022.	5.2	34
114	Properties and clinical utility of topotecan fluorescence: uses for retinoblastoma. <i>British Journal of Ophthalmology</i> , 2015, 99, 1320-1322.	3.9	6
115	The Classification of Vitreous Seeds in Retinoblastoma and Response to Intravitreal Melphalan. <i>Ophthalmology</i> , 2015, 122, 1173-1179.	5.2	113
116	Psychosocial Outcomes in Adult Survivors of Retinoblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3608-3614.	1.6	38
117	Treatment of Retinoblastoma in 2015. <i>JAMA Ophthalmology</i> , 2015, 133, 1341.	2.5	208
118	Anterior Ocular Toxicity of Intravitreal Melphalan for Retinoblastoma. <i>JAMA Ophthalmology</i> , 2015, 133, 1459.	2.5	41
119	Swept-Source Optical Coherence Tomography Features of Choroidal Nevi. <i>American Journal of Ophthalmology</i> , 2015, 159, 169-176.e1.	3.3	42
120	Risk Factors for Severe Neutropenia following Intra-Arterial Chemotherapy for Intra-Ocular Retinoblastoma. <i>PLoS ONE</i> , 2014, 9, e108692.	2.5	36
121	Electroretinogram Monitoring of Dose-Dependent Toxicity after Ophthalmic Artery Chemosurgery in Retinoblastoma Eyes: Six Year Review. <i>PLoS ONE</i> , 2014, 9, e84247.	2.5	39
122	What Do We Know About Intraocular Carboplatin?. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 688-690.	1.4	5
123	Update on Ophthalmic Oncology 2013. <i>Asia-Pacific Journal of Ophthalmology</i> , 2014, 3, 241-256.	2.5	1
124	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2397.	7.4	359
125	Tethered Vitreous Seeds Following Intravitreal Melphalan for Retinoblastoma. <i>JAMA Ophthalmology</i> , 2014, 132, 1024.	2.5	10
126	Non-selectivity of ERG reductions in eyes treated for retinoblastoma. <i>Documenta Ophthalmologica</i> , 2014, 128, 13-23.	2.2	19



#	ARTICLE	IF	CITATIONS
127	Retinoblastoma: Saving Life with Vision. Annual Review of Medicine, 2014, 65, 171-184.	12.2	81
128	Risk of Subsequent Malignant Neoplasms in Long-Term Hereditary Retinoblastoma Survivors After Chemotherapy and Radiotherapy. Journal of Clinical Oncology, 2014, 32, 3284-3290.	1.6	103
129	Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature, 2014, 514, 385-388.	27.8	187
130	Local and Systemic Toxicity of Intravitreal Melphalan for Vitreous Seeding in Retinoblastoma. Ophthalmology, 2014, 121, 1810-1817.	5.2	147
131	<sup>106</sup> Ru plaque brachytherapy for uveal melanoma: Factors associated with local tumor recurrence. Brachytherapy, 2014, 13, 584-590.	0.5	34
132	Death by Water: Precautionary Water Submersion for Intravitreal Injection of Retinoblastoma Eyes. Open Ophthalmology Journal, 2014, 8, 7-11.	0.2	22
133	Retinoblastoma Intra-arterial Chemotherapy. , 2014, , 303-311.		0
134	Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Documenta Ophthalmologica, 2013, 126, 79-84.	2.2	34
135	Ophthalmic Artery Chemosurgery for Retinoblastoma Prevents New Intraocular Tumors. Ophthalmology, 2013, 120, 560-565.	5.2	28
136	Ocular manipulation reduces both ipsilateral and contralateral electroretinograms. Documenta Ophthalmologica, 2013, 127, 113-122.	2.2	12
137	Update on Ophthalmic Oncology 2012. Asia-Pacific Journal of Ophthalmology, 2013, 2, 119-131.	2.5	3
138	A Synergetic Screening Approach with Companion Effector for Combination Therapy: Application to Retinoblastoma. PLoS ONE, 2013, 8, e59156.	2.5	19
139	Carboplatin + <sup>125</sup> I Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma. PLoS ONE, 2013, 8, e72441.	2.5	47
140	Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. British Journal of Ophthalmology, 2012, 96, 1270.1-1271.	3.9	21
141	Variation of Second Cancer Risk by Family History of Retinoblastoma Among Long-Term Survivors. Journal of Clinical Oncology, 2012, 30, 950-957.	1.6	98
142	Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. British Journal of Ophthalmology, 2012, 96, 499-502.	3.9	139
143	Management of high-risk retinoblastoma. Expert Review of Ophthalmology, 2012, 7, 61-72.	0.6	2
144	Success of Intra-arterial Chemotherapy (Chemosurgery) for Retinoblastoma. JAMA Ophthalmology, 2012, 130, 180.	2.4	27

#	ARTICLE	IF	CITATIONS
145	Letter to the Editor. Journal of Neurosurgery, 2012, 116, 470-472.	1.6	1
146	ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma. British Journal of Ophthalmology, 2012, 96, 877-880.	3.9	21
147	PHARMACOKINETIC ANALYSIS OF TOPOTECAN AFTER SUPERSELECTIVE OPHTHALMIC ARTERY INFUSION AND PERIOCLAR ADMINISTRATION IN A PORCINE MODEL. Retina, 2012, 32, 387-395.	1.7	33
148	INTRAARTERIAL CHEMOTHERAPY FOR KISSING MACULA TUMORS IN RETINOBLASTOMA. Retinal Cases and Brief Reports, 2012, 6, 209-211.	0.6	3
149	Periocular carboplatin for retinoblastoma: long-term report (12â€¦years) on efficacy and toxicity: Figure 1. British Journal of Ophthalmology, 2012, 96, 881-883.	3.9	29
150	Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. British Journal of Ophthalmology, 2012, 96, 1300-1303.	3.9	70
151	Intra-arterial Chemotherapy for Retinoblastoma. Ophthalmology, 2012, 119, 1720-1721.	5.2	14
152	Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma. PLoS ONE, 2012, 7, e44322.	2.5	70
153	Ophthalmic Artery Chemosurgery for Less Advanced Intraocular Retinoblastoma: Five Year Review. PLoS ONE, 2012, 7, e34120.	2.5	57
154	Pharmacokinetic Analysis of Melphalan after Superselective Ophthalmic Artery Infusion in Preclinical Models and Retinoblastoma Patients. , 2012, 53, 4205.		57
155	Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment. Pediatric Blood and Cancer, 2012, 59, 859-864.	1.5	36
156	Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. Gynecologic Oncology, 2012, 124, 254-259.	1.4	43
157	Intraocular Hemorrhage After Intra-Arterial Chemotherapy for Retinoblastoma in Sickle Cell Trait. Open Ophthalmology Journal, 2012, 6, 1-3.	0.2	9
158	Intra-arterial and Oral Digoxin Therapy for Retinoblastoma. Ophthalmic Genetics, 2011, 32, 147-150.	1.2	22
159	Intra-arterial Chemotherapy for the Management of Retinoblastoma. JAMA Ophthalmology, 2011, 129, 732.	2.4	399
160	Chemosurgery for Retinoblastoma. JAMA Ophthalmology, 2011, 129, 1492.	2.4	43
161	Sinonasal adenocarcinoma: A rare second malignancy in long term retinoblastoma survivors. Pediatric Blood and Cancer, 2011, 57, 693-695.	1.5	3
162	Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastoma. Middle East African Journal of Ophthalmology, 2010, 17, 207.	0.3	43

#	ARTICLE	IF	CITATIONS
163	Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. , 2010, 51, 2126.		47
164	Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: 'chemosurgery' The first Stallard lecture. British Journal of Ophthalmology, 2010, 94, 396-399.	3.9	41
165	Bilateral Superselective Ophthalmic Artery Chemotherapy for Bilateral Retinoblastoma: Tandem Therapy. JAMA Ophthalmology, 2010, 128, 370.	2.4	92
166	Superselective Ophthalmic Artery Chemotherapy as Primary Treatment for Retinoblastoma (Chemosurgery). Ophthalmology, 2010, 117, 1623-1629.	5.2	177
167	Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides. , 2009, 50, 3065.		46
168	Published International Classification of Retinoblastoma (ICRB) Definitions Contain Inconsistencies—An Analysis of Impact. Ophthalmic Genetics, 2009, 30, 40-44.	1.2	55
169	A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma. , 2009, 50, 1492.		48
170	Choroidal melanoma responses after brachytherapy treatment. Acta Ophthalmologica, 2009, 70, 687-689.	1.1	3
171	Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Documenta Ophthalmologica, 2009, 119, 13-22.	2.2	79
172	Mutations and cancer: one or two historical perspectives?. Lancet Oncology, The, 2009, 10, 834.	10.7	7
173	A Phase I/II Study of Direct Intraarterial (Ophthalmic Artery) Chemotherapy with Melphalan for Intraocular Retinoblastoma. Ophthalmology, 2008, 115, 1398-1404.e1.	5.2	444
174	Genes and environment: effects on the development of second malignancies in retinoblastoma survivors. Expert Review of Ophthalmology, 2008, 3, 51-61.	0.6	15
175	The Adverse Events of Chemotherapy for Retinoblastoma. JAMA Ophthalmology, 2008, 126, 862.	2.4	43
176	Fibrin Sealant for Retinoblastoma: Where Are We?. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 433-438.	1.4	27
177	Retinoblastoma: what is new in 2007—2008. Current Opinion in Ophthalmology, 2008, 19, 526-534.	2.9	50
178	Risk of Soft Tissue Sarcomas by Individual Subtype in Survivors of Hereditary Retinoblastoma. Journal of the National Cancer Institute, 2007, 99, 24-31.	6.3	206
179	Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Ophthalmology, 2007, 114, 1378-1383.	5.2	201
180	Current Management Strategies for Intraocular Retinoblastoma. Drugs, 2007, 67, 2173-2185.	10.9	41

#	ARTICLE	IF	CITATIONS
181	A phase II trial of carboplatin for intraocular retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2007, 49, 643-648.	1.5	52
182	Tadalafil-Induced Subretinal and Choroidal Hemorrhage in a Patient With an Unsuspected Uveal (Choroidal and Ciliary Body) Melanoma. <i>JAMA Ophthalmology</i> , 2006, 124, 1058.	2.4	7
183	An Aggressive Bone Marrow Evaluation Including Immunocytology With GD2 for Advanced Retinoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 369-373.	0.6	27
184	Retinoblastoma in the 20th Century: Past Success and Future Challenges The Weisenfeld Lecture. , 2005, 46, 2684.		142
185	Risk of New Cancers After Radiotherapy in Long-Term Survivors of Retinoblastoma: An Extended Follow-Up. <i>Journal of Clinical Oncology</i> , 2005, 23, 2272-2279.	1.6	453
186	Periocular Mucosa-Associated Lymphoid/Low Grade Lymphomas: Treatment With Antibiotics. <i>American Journal of Ophthalmology</i> , 2005, 140, 729-730.	3.3	70
187	Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma. <i>Ophthalmology</i> , 2004, 111, 984-991.	5.2	62
188	Visual Fields in Retinoblastoma Survivors. <i>JAMA Ophthalmology</i> , 2004, 122, 1324.	2.4	22
189	UPDATE ON RETINOBLASTOMA. <i>Retina</i> , 2004, 24, 828-848.	1.7	222
190	Outcome Following Initial External Beam Radiotherapy in Patients With Reese-Ellsworth Group Vb Retinoblastoma. <i>JAMA Ophthalmology</i> , 2004, 122, 1316.	2.4	106
191	New retinoblastoma tumor formation in children initially treated with systemic carboplatin. <i>Ophthalmology</i> , 2003, 110, 1989-1994.	5.2	42
192	(Neonatal) Retinoblastoma in the First Month of Life. <i>JAMA Ophthalmology</i> , 2002, 120, 738.	2.4	49
193	Osteogenic sarcoma in a survivor of metastatic germline retinoblastoma: the possible influence of human growth hormone. <i>Journal of Pediatric Ophthalmology and Strabismus</i> , 2002, 39, 347-8.	0.7	1
194	Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. <i>Ophthalmology</i> , 2001, 108, 1868-1876.	5.2	126
195	The measurement of three dimensional dose distribution of a ruthenium-106 ophthalmological applicator using magnetic resonance imaging of BANG polymer gels1. <i>Journal of Applied Clinical Medical Physics</i> , 2001, 2, 85-89.	1.9	9
196	Successful treatment of metastatic retinoblastoma. <i>Cancer</i> , 2000, 89, 2117-2121.	4.1	116
197	Hereditary Retinoblastoma and Risk of Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2000, 92, 2037-2039.	6.3	62
198	Second nonocular cancers in retinoblastoma: a unified hypothesis The Franceschetti Lecture. <i>Ophthalmic Genetics</i> , 1999, 20, 193-204.	1.2	62

#	ARTICLE	IF	CITATIONS
199	A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. <i>Ophthalmology</i> , 1999, 106, 1947-1950.	5.2	187
200	Familial retinoblastoma, where and when?. <i>Acta Ophthalmologica</i> , 1998, 76, 334-338.	0.3	37
201	Second nonocular tumors in survivors of bilateral retinoblastoma. <i>Ophthalmology</i> , 1998, 105, 573-580.	5.2	319
202	THE TOPOGRAPHY OF BILATERAL RETINOBLASTOMA LESIONS. <i>Retina</i> , 1996, 16, 232-239.	1.7	46
203	Retinoblastoma Aqueous Humor: Aromatic Amino Acids. <i>Ophthalmic Paediatrics and Genetics</i> , 1993, 14, 127-130.	0.4	4
204	Correlations between Age at Diagnosis and Time Course for New Intraocular Tumors. <i>Ophthalmic Paediatrics and Genetics</i> , 1992, 13, 1-7.	0.4	18
205	Radiation therapy for retinoblastoma: comparison of results with lens-sparing versus lateral beam techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 15, 567-574.	0.8	63
206	Second Nonocular Tumors in Retinoblastoma Survivors. <i>Ophthalmology</i> , 1984, 91, 1351-1355.	5.2	444
207	Retinoblastoma: Diagnosis and Management. <i>Ca-A Cancer Journal for Clinicians</i> , 1982, 32, 130-140.	329.8	76
208	Second Tumors in Nonirradiated Bilateral Retinoblastoma. <i>American Journal of Ophthalmology</i> , 1979, 87, 624-627.	3.3	152